COVID-19 Impact on Vaccines & Drugs Market – Global Forecast to 2025

2020-05-04
Price :
Published : May-2020
No. of Pages : 66

“The global COVID 19 vaccines market is projected to grow at a CAGR of -14.9% during the forecast period.”

The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the global COVID-19 vaccines market is majorly attributed to the increasing number of people infected with COVID-19 and growing funding for vaccine development.

“The global COVID 19 drugs market is projected to grow at a CAGR of -57.8% during the forecast period.”

The global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of COVID-19 drugs market is attributed primarily to use of repurposed drugs for compassionate use and the emergence of alternative therapies such as convalescent plasma therapy which were used earlier for treating epidemic diseases such as SARS, MERS, and H1N1. Furthermore, collaborations between global organizations and governments of various nations to promote the supply of essential drugs and medical supplies will fuel market growth. However, factors such as herd immunity, and uncertainty over the efficacy of vaccines and drugs are expected to hinder the market growth.

Currently, the R&D landscape for COVID-19 vaccines includes 115 vaccine candidates. The most advanced candidates that have recently moved into clinical development are:

  • mRNA-1273 from Moderna
  • Ad5-nCoV from CanSino Biologics
  • INO-4800 from Inovio
  • LV-SMENP-DC and pathogen-specific aAPC from Shenzhen Geno-Immune Medical Institute

Funding from global governments and foundations is promoting the growth of the market

Incentives are needed to engage manufacturers for the large-scale capacity to guarantee sufficient production of SARS-CoV-2 vaccines. In line with this, various global organizations have come forward to expedite the process, such as Gavi, CEPI, and WHO. However, considering the pandemic scenario of COVID-19, much stronger initiatives are required.

In April 2020, the Bill and Melinda Gates Foundation plans to help fund factories for seven promising vaccines, even before seeing conclusive data. The foundation aims to help scale up manufacturing during testing, rather than after the vaccines have passed the trials.

Besides the most promising Moderna program, several other big pharma companies are involved in COVID-19 vaccine work. Johnson & Johnson has pledged a manufacturing scale-up to 1 billion doses for its federally partnered program. Meanwhile, Sanofi has two partnerships underway—one with the federal government and another with Translate Bio.

Vaccine manufacturing ramp-up to drive the growth further

While global drug makers are pouring massive resources into developing targeted therapies and vaccines, contract development and manufacturing organizations (CDMOs) are finding ways to ramp up the production of vaccines. In line with this, a new CDMO from Belgium’s Univercells is offering its expertise to help drug makers scale up their manufacturing.

Pfizer and BioNTech have laid out plans for manufacturing their candidates for trials and producing millions of doses if trials succeed. The companies expect to have millions of doses of a COVID-19 vaccine ready to go by year-end if the companies begin human testing as planned by late April. Pfizer and BioNTech are hoping to advance multiple mRNA vaccine candidates.

Currently, around 155 molecules are under clinical investigation, and approximately 45 molecules are under preclinical development to be targeted against COVID-19. In this list, four promising drugs have been repurposed for use against COVID-19.

  • Remdesivir
  • Chloroquine and hydroxychloroquine
  • Lopinavir and ritonavir (and that same combination plus interferon-beta)
  • An immune system messenger that can help stop the multiplication of viruses.

Researchers and physicians in several countries are focusing on various other existing drugs to examine their potential to treat COVID-19. Chinese authorities, which have been dealing with the virus longer, are recommending Arbidol (umifenovir), which has not been approved in Western countries, as well as old antivirals ribavirin and interferon-alpha. Similarly, Avigan (favipiravir) by Fujifilm has shown promise in the treatment of COVID-19.

As the maximum number of molecules are repurposed drugs that are already approved for other infections and inflammatory diseases, higher stages of development (namely phase 2 trials) hold the largest share. China, along with other Asian countries, holds the largest share of the number of clinical trials being conducted, followed by Europe and the US. Small molecules hold the largest share, followed by monoclonal antibodies and plasma and cell therapy.

AI-powered technologies are making the drug discovery process more efficient and substantially improve success rates at the early stages of drug development. Artificial intelligence algorithms ingest and analyze a vast amount of information and can identify potential drug candidates in lesser time. Such factors will expedite the drug development process.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type (Supply-side): Tier 1: 29%, Tier 2: 37%, and Tier 3: 34%
  • By Category (Demand-side): Pharmaceutical & Biotechnology Companies: 55%, Hospital & Reference Laboratories: 35%, and Academic & Research Institutes: 10%
  • By Designation: C-level: 35%, Director-level: 25%, and Others: 40%
  • By Region: North America: 35%, Europe: 32%, Asia: 22%, and the RoW: 11%

Some of the major players in the COVID-19 vaccines market include Pfizer Inc. (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc. (UK), Sanofi (France) Serum Institute of India (India), among others. Major players in the COVID-19 drugs market include Gilead Sciences, Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), and Janssen Pharmaceuticals, Inc. (Belgium), among others.

Research Coverage:

This report describes and studies the global COVID-19 vaccines and drugs market, current pipeline of vaccines and drugs by phase by companies, competitive landscape, a view point on COVID-19 pipeline, the impact of COVID-19 on other vaccines and drugs in the portfolio/other under development vaccines and drugs, macroeconomic indicators (drivers, restraints, new opportunities), post-COVID-19 approval scenario, challenges in approval/production/supply, strategies to overcome challenges, historical examples (SARS, MERS, Ebola, H1N1), new strategies, strategies to ramp up production at pandemic level, historical examples, and new strategies.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the developmental pipeline of the top players in the COVID-19 vaccines and drugs market. The report analyzes the current pipeline of vaccines and drugs by phase by companies, competitive landscape, a view point on COVID-19 pipeline, the impact of COVID-19 on other vaccines, and drugs in the portfolio/other under development vaccines and drugs and regional analysis.
  • Product Development/Innovation: Detailed insights on upcoming vaccines and drugs based on innovative technologies, research and development activities, and product launches in the COVID-19 vaccines and drugs market.
  • Market Development: Comprehensive information about lucrative markets. The report analyzes the markets for vaccines and drugs across regions.
  • Market Diversification: Exhaustive information about developmental products, recent developments, and investments in the COVID-19 vaccines and drugs market.
  • Competitive Assessment: In-depth assessment of strategies, products, distribution networks, and manufacturing capabilities of the leading players in the COVID-19 vaccines and drugs market.
Filed in: Pharmaceutical
Publisher : marketsandmarkets
More Reports
Title Price Buy Now

Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) – Global Forecast to 2025

 “Growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD) is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period. Growth in the plasma fractionation market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-ant......
$4950

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (Practice Management, e-Prescribing, PHM, Health Analytics, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User – Global Forecast to 2025

“Government support to increase adoption of EHR solutions is expected to drive the overall growth of the ambulatory EHR market.” The ambulatory EHR market is expected to reach USD 6.8 billion by 2025 from USD 5.2 billion in 2020, at a CAGR of 5.7% during the forecast period of 2020 to 2025. Growth in the global ambulatory EHR market can primarily be attributed to various factors such as government support for the adoption of EHR solutions, increasing number of outpatient care centers, growing patient volume due to the global outbreak of COVID-19, and the need to curtail healthcare costs. On the other hand, market growth is limited to a certain extent due to factors such as reluctance to adopt EHR solutions in developing countries, heavy infrastructure investments, and the high cost ......
$4950

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020" provides an overview of Neisseria meningitidis Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Neisseria meningitidis Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using Glob......
$2500

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020

Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Oropharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Oropharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical tr......
$2500

Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020

Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020" provides an overview of Actinic (Solar) Keratosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Actinic (Solar) Keratosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020" provides an overview of Functional (Non Ulcer) Dyspepsia Clinical trials scenario. This report provides top line data relating to the clinical trials on Functional (Non Ulcer) Dyspepsia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDa......
$2500

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinica......
$2500

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Schizoaffective Disorder Global Clinical Trials Review, H2, 2020

Schizoaffective Disorder Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Schizoaffective Disorder Global Clinical Trials Review, H2, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Schizoaffective Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy